The Russian pharmaceutical market is showing positive dynamics these days, despite the ever-tightening sanctions regime and the growing isolation of Russia in the international arena, reports The Pharma Letter’s local correspondent.
According to the latest report of the Russian research agency Kontur.Fokus, over the past three years, the Russian pharmaceutical industry has grown both in the number of players and in total revenue.
Despite the exodus of some foreign players, that was compensated by domestic drugmakers, many of which decided to accelerate their expansion in the domestic market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze